THC Inhibits Atherosclerosis in Mice

The Journal of Neuroendocrinology published a review last year (2009), which suggests that oral THC may significantly reduce plaque development in diseases associated with obesity, such as atherosclerosis.

Atherosclerosis, a condition of plaque deposits in the lining of the arteries that results from a diet high in cholesterol, is one of the major causes of death in overweight/obesity-related disease. The plaque is created as a by-product of specific cells, called macrophages, when they consume fatty particles. As the plaque gathers, the walls of arteries become stiff and eventually collapse.

The study suggests that THC interacts directly with macrophages and suppresses their plaque-creating abilities through the Cannabinoid Type II receptor (CB2R). Immune cells in our body, such as macrophages, have many more cannabinoid receptors expressed on their surface - this makes them an exceptionally strong target for cannabis-based medicines.

The authors note that oral administration of low doses of THC resulted in significant inhibition of plaque development, an effect that could be reversed by blocking the CB2R.

What does this mean for humans? It is difficult to say without further research. But the results are hopeful. Given the politics surrounding cannabis, it might be a long while before the FDA approves a study in humans on cannabis and atherosclerosis. On the other hand, research such as this shows not only that we have only begun to investigate the healing potential of this remarkable natural compound, but the importance of advocating for a more open environment for future research.